Val75 of HIV-1 reverse transcriptase (RT) plays a role in positioning the template nucleotide +1, during the formation of the ternary complex. Mutations such as V75M and V75A emerge in patients infected with HIV-1 group M-subtype B and group O variants, after failing treatment with stavudine (d4T) and other nucleoside RT inhibitors. V75I is an accessory mutation of the Q151M multi-drug resistance complex of HIV-1 RT, and is rarely associated with thymidine analogue resistance mutations (TAMs). In vitro, it confers resistance to acyclovir. TAMs confer resistance to zidovudine (AZT) and d4T by increasing the rate of ATPmediated excision of the terminal nucleotide monophosphate (primer unblocking). In a wild-type HIV-1 group O RT sequence context, V75A and V75M conferred increased excision activity on d4T-terminated primers, in the presence of pyrophosphate (PPi). In contrast, V75I decreased the PPi-mediated unblocking efficiency on AZT and d4T-terminated primers, in different sequence contexts (i.e. wild-type group M-subtype B or group O RTs).
Val75 of HIV-1 reverse transcriptase (RT)
plays a role in positioning the template nucleotide +1, during the formation of the ternary complex. Mutations such as V75M and V75A emerge in patients infected with HIV-1 group M-subtype B and group O variants, after failing treatment with stavudine (d4T) and other nucleoside RT inhibitors. V75I is an accessory mutation of the Q151M multi-drug resistance complex of HIV-1 RT, and is rarely associated with thymidine analogue resistance mutations (TAMs). In vitro, it confers resistance to acyclovir. TAMs confer resistance to zidovudine (AZT) and d4T by increasing the rate of ATPmediated excision of the terminal nucleotide monophosphate (primer unblocking). In a wild-type HIV-1 group O RT sequence context, V75A and V75M conferred increased excision activity on d4T-terminated primers, in the presence of pyrophosphate (PPi). In contrast, V75I decreased the PPi-mediated unblocking efficiency on AZT and d4T-terminated primers, in different sequence contexts (i.e. wild-type group M-subtype B or group O RTs).
Interestingly, in the sequence context of an excision-proficient RT (i.e., M41L/A62V/T69SSS/K70R/T215Y), the introduction of V75I led to a significant decrease of its ATP-dependent excision activity on AZT-, d4T-, and acyclovir- The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) plays a pivotal role in the viral life cycle and therefore, it is an important target for antiretroviral drugs such as nucleoside and nucleotide RT inhibitors (NRTIs) (1, 2) . Once phosphorylated by cellular kinases to their active triphosphate (TP) forms, NRTIs compete with the natural deoxynucleoside triphosphates (dNTPs) for incorporation by RT into the nascent reverse transcript. Since NRTIs lack a 3´-OH group, their incorporation results in chain termination (3, 4) . The development of resistance remains a major problem in the treatment of HIV-1 infections. HIV-1 becomes resistant to NRTIs by (i) improving discrimination against the RT inhibitors (5-7), or (ii) by increasing the RT's ability to remove 3´-terminal chainterminator inhibitors from blocked DNA primers, through phosphorolysis mediated by ATP or pyrophosphate (PPi) (8, 9) .
Both resistance mechanisms can be relevant in the acquisition of multidrug resistance (for recent reviews, see refs. 10, 11) . Thus, viral RTs bearing mutations A62V, V75I, F77L, F116Y and Q151M showed decreased discrimination efficiencies against the triphosphorylated forms of thymidine analogues such as zidovudine (AZT: β-D-(+)-3´-azido-3´-deoxythymidine) or stavudine (d4T: β-D-(+)-2´,3´-didehydro-2´,3´-dideoxythymidine), as well as didanosine, zalcitabine and abacavir (6, 12, 13) . These observations were in agreement with the high-level resistance to those inhibitors shown in phenotypic assays, by HIV variants carrying those mutations in their RTs (14, 15) . On the other hand, resistance to all approved NRTIs may be increased by the accumulation of thymidine analogue resistance mutations (TAMs) (i.e. M41L, D67N, K70R, L210W, T215F or Y and K219E or Q) in the absence, or in the presence of dipeptide insertions between residues 69 and 70.
Biochemical studies have shown that TAMs confer resistance to AZT and other NRTIs by accelerating the rate at which the blocking AZT monophosphate (MP) (or other nucleoside analogue monophosphate) is removed through phosphorolytic cleavage. RTs containing mutations M41L, A62V, T69S, K70R and T215Y, plus a Ser-Ser insertion between codons 69 and 70 showed very high levels of excision activity with primers terminated with AZTMP (16) . Resistance mechanisms are not mutually exclusive. Thus, A62V, an accessory mutation of the Q151M complex, was reported to increase the ATP-dependent phosphorolytic activity on thymidine analogue-terminated primers of RTs bearing dipeptide insertions (16) , while the excision activity promoted by the presence of TAMs can be modulated by mutations that influence nucleotide discrimination (e.g. K65R, L74V, M184V) (17) (18) (19) (20) (21) .
V75I is an accessory mutation of the Q151M multidrug resistance complex of HIV-1 RT and contributes to increase zidovudine, stavudine, didanosine and zalcitabine resistance in the presence of F77L, F116Y and Q151M (15, 22, 23) . In addition, V75I has been recently identified as a major acyclovir resistance mutation in cells co-infected with HIV-1 and herpes simplex virus (24, 25) . Structural analysis of HIV-1 RT showed that Val75 plays a role in positioning the template nucleotide +1, once the ternary complex is formed (26) . The side chain of Val75 interacts with the side chain of Phe77 to maintain the structure of the fingers subdomain. Mutations such as V75M, V75T and V75A have been reported to occur in about 4% of patients infected with HIV-1 group M:subtype B, and receiving nucleoside RT inhibitors (NRTIs), particularly d4T (http://hivdb.stanford.edu; 27, 28) . In vitro, V75T confers low-level resistance to stavudine and other NRTIs (29) . Mutations at codon 75 have been also detected in treated-patients infected with other clades of HIV-1. Thus, V75M has been found in CRF01_AE-infected patients (30) , while V75A and V75M have been selected in the absence and in the presence of TAMs, respectively, in stavudine-treated patients infected with HIV-1 group O (31).
In this study, we have examined the effects on stavudine resistance of the amino acid substitutions V75A, V75M and V75I in the sequence context of a wild-type HIV-1 group O RT. Our data show that V75I reduces ATP-and PPi-mediated excision of thymidine analogues in different sequence contexts, including wild-type variants of group Msubtype B and group O HIV-1 RTs, as well as multidrug-resistant enzymes containing either the Q151M complex, or the combination M41L/A62V/T69SSS/K70R/T215Y. These results provide evidence of the antagonism between V75I and TAMs.
EXPERIMENTAL PROCEDURES
Reverse transcriptases-Expression and purification of BH10_WT RT (wild-type HIV-1 BH10 RT), BH10_V75I RT (HIV-1 BH10 RT containing the mutation V75I) and Q151M c RT (HIV-1 NL4-3 RT containing mutations A62V/V75I/F77L/F116Y/Q151M) was performed with modified versions of plasmid p66RTB, as previously described (12, (32) (33) (34) . For high-level expression of wildtype HIV-1 group O (O_WT) RT, an insert derived from cleavage with EcoRI and XhoI of plasmid pRT6, and containing the RTcoding sequence of the ESP49 variant (35) , was cloned at the corresponding sites of P66RTB(SS) (36) . The vector used for highlevel expression of the p66 subunit of the MAK_SSSY RT, containing a Ser-Ser insertion between codons 69 and 70, and mutations M41L, A62V, T69S, K70R and T215Y (16) , was obtained after cloning the SalI-MscI insert purified after cleavage of pRT6-derived plasmid, at the appropriate sites of p66RTB(Q151M c ) (12) . An XhoI site was introduced nine nucleotides upstream of the sequence encoding for the His 6 tag in order to eliminate the stop codon generated during the cloning process. Site-directed mutagenesis was carried out with the QuikChange TM SiteDirected Mutagenesis kit (Stratagene) by following the manufacturer's instructions, and using the following mutagenic primers: 5'-GGAATCAGGAAAATACTCGAGTCGAC TCACCACC-3' and 5'-GGTGGTGAGTCG-ACTCGAGTATTTTCCTGATTCC-3'. The introduced mutations were confirmed by DNA sequencing. RT p66 subunits carrying a His 6 tag at their C-terminus were coexpressed with HIV-1 protease in E. coli XL1 Blue to obtain p66/p51 heterodimers, which were later purified by ionic exchange followed by affinity chromatography (32, 33) . RT concentrations were determined by active site titration as previously described (37) .
Other mutant RTs were also generated with the QuikChange TM Site-Directed Mutagenesis kit, but using plasmids p66RTB(O_WT), p66RTB(MAK_SSSY) or p66RTB(Q151M C _I75V (relevant codons underlined). After mutagenesis, the entire RT coding regions were sequenced, and if correct, used for RT expression and purification.
Nucleotides and template/primers-Stock solutions (100 mM) of dNTPs and ATP were obtained from GE Healthcare. AZTTP was purchased from Moravek Biochemicals (Brea, California). Acyclovir-TP and d4TTP were obtained from Sierra Bioresearch (Tucson, Arizona). The α-boranophosphate derivative of d4TTP (α-BH 3 -d4TTP) was synthesized as previously described (38, 39) , and its R p and S p diastereoisomers were purified by reversephase HPLC (40) . Before use, nucleoside-TPs were treated with inorganic pyrophosphatase (Roche) to remove traces of PPi, as described (41) . DNA oligonucleotides 21P (5'-ATACTTTAACCATATGTATCC-3'), 25PGA (5'-TGGTAGGGCTATACATTCTT-GCAGG-3'), 31T (5'-TTTTTTTTTAGGAT-ACATATGGTTAAAGTAT-3'), D38 (5'-GGGTCCTTTCTTACCTGCAAGAATGTA TAGCCCTACCA-3'), and D38C (5'-GGGTCCTTTATTCCCTGCAAGAATGTA TAGCCCTACCA-3') were obtained from Life Technologies. Oligonucleotides 21P and 25PGA were labeled at their 5' termini with [γ-32 P]ATP (Perkin Elmer) and T4 polynucleotide kinase (Promega), and then annealed to their corresponding templates (31T and D38, respectively). Template/primer 31T/21P was used in rapid quench incorporation experiments, while D38/25PGA was used in chain terminator excision assays, and for the determination of kinetic parameters of ATP-dependent phosphorolysis.
Chain-terminator excision assays-RTcatalyzed DNA rescue reactions were performed with D38/25PGA DNA duplexes, as previously described (42, 43) . Briefly, the phosphorylated template/primer (30 nM) was preincubated at 37°C for 10 min in the presence of the corresponding RT at 12-24 nM active enzyme concentration, in 50 mM Hepes buffer (pH 7.0), containing 15 mM NaCl, 15 mM magnesium acetate, 130 mM potassium acetate, 1 mM dithiothreitol, and 5% (w/v) polyethylene glycol 6000. Reactions were initiated by adding an equal amount of preincubation buffer containing the nucleoside RT inhibitor in its triphosphorylated form, at a final concentration of 25 µM. After incubating the samples at 37°C for 30 min, rescue reactions were initiated by adding a mixture of all dNTPs at a final concentration of 100 µM, in the presence of sodium PPi (200 µM) or ATP (3.2 mM) depending on the assay. Since the next complementary dNTP (dATP, in our assay conditions) has an inhibitory effect on the rescue reaction, time-courses of the unblocking and extension reactions were carried out in the presence of 1 µM dATP. In experiments designed to assess the inhibitory effect of dATP, extension reactions were incubated for 5-20 min in the presence of different concentrations of dATP. In all of those determinations, the amount of rescued primer was below 30%. Reactions were stopped by adding an equal amount of sample loading buffer [10 mM EDTA in 90 % formamide containing 3 mg/ml xylene cyanol FF and 3 mg/ml bromophenol blue]. Products were resolved on a denaturing 20% (w/v) polyacrylamide/8 M urea gel, and primer rescue was quantified by phosphorimaging with a BAS 1500 scanner (Fuji) using the program Tina version 2.09 (Raytest Isotopenmessgerate Gmbh, Staubenhardt, Germany). 
Pre-steady-state kinetics of single nucleotide incorporation experiments-
where K d and k pol are the equilibrium constant and the catalytic rate constant of the dNTP for RT, respectively. K d and k pol were determined from curve-fitting using Sigma Plot.
Pre-steady-state kinetics of the ATPdependent excision reaction-For these experiments, primer 25PGA was blocked at its 3' end with d4TTP, using terminal deoxynucleotidyl transferase as previously described (41) . Then, the free d4TTP was eliminated with a mini Quick Spin TM column (Roche). Inhibitor-terminated primer was labeled at its 5' terminus with [γ- 32 2+ was performed essentially as described (44) . Briefly, pre-formed complexes in a volume of 20 μl were incubated with a mixture of 2 μl of 500 μM Fe(NH 4 ) 2 SO 4 •6H 2 O and 2 μl of 500 μM dithiothreitol. Reactions were allowed to proceed for 5 min and then stopped by adding 100 μl of a solution containing 0.1 M thiourea, 2 ng/μl tRNA, 10 mM EDTA and 0.6 M sodium acetate. Samples were subsequently precipitated with ethanol and loaded on a 20% denaturing polyacrylamide gel, as described above.
Recombinant virus and drug susceptibility tests-These assays were performed as described (16, 42) . Briefly, full-length RT coding sequence DNA was amplified by PCR from the different BH10 expression plasmids carrying the appropriate RT using the IN5 (5´-AATTTTCCCATTAGTCCTATTGAAACT GTACCA-3´) and IN3 (5´-TCTATTCCAT-CYAAAAATAGTACTTTCCTGATTCC-3´) primers. The PCR products were then co- HIV-1 drug susceptibility data were obtained after infecting 30,000 MT-4 cells with 100 50% tissue culture infective doses of virus, at a multiplicity of infection of 0.003, by exposing the HIV-1-infected cultures to various concentrations of each drug (five-fold dilutions). After the MT-4 cells were allowed to proliferate for five days, the number of viable cells was quantified by a tetrazoliumbased colorimetric method (MTT method) as described elsewhere (47) . Table 1) . These results suggested that V75I could confer some resistance, although differences with the wild-type enzyme were relatively small or non-significant.
RESULTS

Discrimination between 2´-deoxythymidine
Effects of substituting Val75 in wild-type HIV-1 RTs on the excision of thymidine analogues from blocked DNA primers -The ability of
RTs to unblock d4TMP-terminated primers was assessed by using the template/primer shown in Fig. 1A . These experiments were carried out in two steps. First, the enzyme and the template/primer were incubated in the presence of d4TTP to generate a terminated 26-nucleotide primer. Then, unblocking and extension reactions were carried out by adding a mixture of dNTPs and PPi (200 μM) or ATP (3.2 mM). These assays revealed that in comparison with the wild-type HIV-1 group O RT, mutants V75A and V75M had increased excision activity on d4TMP-terminated primers, thereby promoting stavudine resistance (Fig. 1B) . Interestingly, the mutation V75I produced a significant decrease in the PPi-mediated excision activity. This effect was also observed when the V75I mutation was introduced in the HIV-1 group M:subtype B sequence context (i.e. in the RT of the BH10 strain), but the differences between mutants V75A, V75M and the wild-type enzyme were not significant (Fig. 1C) .
The reduced phosphorolytic activity of RTs bearing the V75I mutation was also observed in ATP-mediated excision assays, although the efficiency of the unblocking reaction was relatively low. After incubating for 30 min in the presence of 3.2 mM ATP, in the conditions described in the legend to Fig. 1 , O_WT, O_V75I, BH10_WT and BH10_V75I RTs were able to unblock and extend 9.5, 6.0, 12.2 and 8.0% of the d4TMP-terminated primer, respectively. The diminished excision activity associated with the V75I mutation was also observed with primers blocked with AZTMP, and was independent of the RT sequence context, as shown in Fig. 1D .
Effects of V75I on the excision activity of multidrug-resistant RTs -The effects of substituting Ile for Val75 were also analyzed in the sequence context of multidrug resistant RTs, such as the one containing the Q151M mutation complex (Q151M c RT) or an excision-proficient RT carrying a Ser-Ser insertion between codons 69 and 70, and mutations M41L, A62V, T69S, K70R and T215Y (MAK_SSSY RT). As shown in Fig.  2 , a reduction in the ATP-or PPi-mediated excision activity on primers terminated with d4TMP was obtained by introducing the V75I mutation in the MAK_SSSY RT. In addition, eliminating the V75I mutation from the Q151M c RT sequence rendered an enzyme with slightly increased excision activity. The largest effects of substituting Val or Ile at position 75 were observed with the MAK_SSSY RT mutant in ATP-dependent phosphorolytic reactions.
The d4TMP excision rates for MAK_SSSY RT and its derivative containing V75I were determined in the presence of 3.2 mM ATP, under single-turnover conditions and using a d4TMP-terminated primer which was previously annealed to a 38-nucleotide template (D38) (Fig. 3) .
MAK_SSSY RT showed an excision rate (k obs ) of 0.178 ± 0.007 min -1 , and the introduction of V75I in the sequence context of MAK_SSSY RT led to a 10-fold decrease of the excision rate (k obs value was 0.0167 ± 0.0014 min -1 (44) were carried out in order to determine the impact of V75I on the translocation status of HIV-1 RT. DNA/DNA duplexes containing the MG48 template and the primer P19 terminated with d4TTP or with AZTTP were used as substrates (Fig. 4) . In the presence of MG48/P19, treatment with Fe 2+ caused site-specific cleavage at positions −17 and −18, which correspond to posttranslocational (P-site complex) and pretranslocational (N-site complex) configurations of the template/primer in the HIV-1 RT. Fe 2+ -mediated cuts were assigned by means of a T-ladder (Fig. 4B) .
As expected, the addition of the next complementary dNTP (i.e. dGTP under our assay conditions) promoted the formation of the 'dead-end' complex and the inhibition of the excision reaction, while leading to a significant increase of the intensity of the band at position -17, corresponding to the post-translocational configuration of the viral RT (Fig. 4B) . On the other hand, foscarnet shifts the translocational equilibrium towards a pre-translocated (and sometimes, hypertranslocated) position (50, 51) (Fig. 4B) . Fig. 4C shows the distribution of pre-and post-translocated complexes in the presence of increasing concentrations of dGTP for the multidrug-resistant mutant M41L/A62V/T69SSS/K70R/T215Y and its derivative containing V75I. The dGTP concentration required to obtain 50% of complexes in the post-translocational stage was >1000 times lower for dd4TMP-than for AZTMP-terminated primers. Differences between M41L/A62V/T69SSS/K70R/T215Y and M41L/A62V/T69SSS/K70R/V75I/T215Y were non-significant for AZTMP-terminated primers.
However, in the presence of d4TMP-terminated primers, the MAK_SSSY RT showed a higher preference for the posttranslocational configuration. Estimates of the concentrations of dGTP required to obtain 50% of the complexes in the posttranslocational stage were 0.29 ± 0.06 μM for MAK_SSSY RT, and 0.62 ± 0.15 for MAK_SSSY_V75I RT.
Other RTs (i.e. wild-type BH10 RT, wild-type group O RT, and the multidrug-resistant mutant A62V/F77L/F116Y/Q151M, as well as their derivatives with V75I) showed similar cleavage patterns, with small differences in the band intensities at positions -17 and -18 (Fig. 5) .
However, higher dGTP concentrations were required to shift the equilibrium towards the post-translocational stage for O_WT and O_V75I RTs than for the other enzymes. Interestingly, in comparison with the mutant BH10_V75I, the BH10_WT RT showed a higher preference for the posttranslocational stage within the range of 0.05-0.5 μM dGTP. However the effects of V75I on the translocational equilibrium of O_WT and A62V/V75I/F77L/F116Y/Q151M RTs were not significant.
These results were also broadly in agreement with site-specific footprinting experiments carried out with the template-primer used in the dNTP inhibition experiments (i.e. D38/25PGA), that showed that V75I had an impact on the formation of the 'dead-end' complex both in the presence of wild-type BH10 RT or in the presence of the mutant M41L/A62V/T69SSS/K70R/T215Y (data not shown).
Further excision experiments with d4TMP-terminated primers showed that the V75I mutation impaired both the ATP-and the PPidependent phosphorolytic activity of the multidrug-resistant RT containing the insertion and the accompanying TAMs (i.e. M41L/A62V/T69SSS/K70R/T215Y), in reactions carried out with DNA duplexes containing an AZTMP-terminated primer (Fig. 6A) . The peptide backbone of Val75 interacts with the 5´ template overhang in the ternary complex of HIV-1 RT, although an indirect effect on Gln151 and other residues in the dNTP binding site could also occur and affect the enzyme's activity (26, 34) . The geometry of the phosphodiester bond at the 3´ end of the primer could interfere with excision. However, the time courses of the excision reactions carried out with primers terminated with the R p and S p diastereoisomers of α-borano derivatives of d4TMP [i.e. α-(R p )-BH 3 -d4TMP and α-(S p )-BH 3 -d4TMP] were almost identical (Fig. 6B) . However, in all cases, the V75I mutation produced a significant decrease in the excision rate, which was larger in ATPdependent phosphorolytic reactions.
Interestingly, V75I also impaired the excision activity on primers terminated with acyclovir (Fig. 6C) , suggesting a broad impact on ATPdependent phosphorolytic activity on primers blocked with several chain-terminating inhibitors. However, it should be noted that V75I impairs the incorporation of acyclovir-TP (25) and therefore, acyclovir excision is not expected to be relevant in vivo.
Phenotypic drug susceptibility of recombinant HIV-1 -Recombinant HIV-1 clones containing the excision-proficient MAK_SSSY RT and its derivative containing V75I (i.e. M41L/A62V/T69SSS/K70R/V75I/T215Y) were assayed to establish the level of resistance to thymidine analogues. As reported in Table 2 , the MAK_SSSY RT conferred >80-fold increased AZT resistance and 5.8-fold increased d4T resistance in comparison with wild-type HIV-1 containing the BH10 RT. The V75I mutation decreased resistance to both thymidine analogues, although the effects were much more significant with AZT.
DISCUSSION
Despite the significant advances in antiretroviral therapy, and the increasing knowledge about drug resistance mutations, interpretation of mutational patterns is often difficult due to poor phenotypic correlates, unexpected interactions between amino acid substitutions involved in resistance and uncertainties on the contribution of secondary mutations in different sequence contexts. Several mutations at codon 75, such as V75A, V75T or V75M have been related to stavudine resistance in major clades of HIV-1 (e.g. group M:subtype B and group O strains) (27, (29) (30) (31) 52) .
Our kinetic analysis of nucleotide incorporation shows that in the sequence context of an HIV-1 group O RT, V75M has only slightly increased discrimination ability between d4TTP and dTTP in comparison with the wild-type enzyme. However, both stavudine-related mutations V75M and V75A were shown to confer increased phosphorolytic activity on d4TMP-terminated primers (Fig. 1) , a result which is consistent with their selection in vivo in stavudine-treated patients which were infected with HIV-1 group O variants (31) . However, these differences were not observed with a prototypic HIV-1 group M:subtype B RT (i.e. BH10 RT).
Interestingly, our analysis shows that V75I has a minor influence on discrimination between d4TTP and dTTP, but impairs thymidine analogue excision in different RT sequence contexts, including wild-type and drug-resistant enzymes ( Figs. 1 and 2) . Reversion of the excision phenotype by V75I was particularly evident with the mutant containing the dipeptide insertion and TAMs such as M41L, K70R and T215Y.
Val75 is located in the β3-β4 hairpin loop (residues 56-77) and plays a role in positioning the template nucleotide +1 during the formation of the ternary complex of RT, duplex DNA and the incoming dNTP (26) . The comparison with the crystal structure of the HIV-1 RT binary complex (53) revealed that in the ternary complex, the distances between the peptide backbones of Val75 and Gln151 and between Val75 and the singlestranded template were reduced (34) . In addition, the side chain of Val75 interacts with residues such as Val60, Phe77 or Tyr146 that are important to maintain the structure of the fingers subdomain while influencing the architecture of the dNTP binding site (52) . It has been shown that in a subtype B HIV-1 RT sequence context, V75T increases d4T excision (52) , while V75I has the opposite effect (this work). Subtle differences affecting the accessibility of the PPi donor to the terminating nucleotide at the 3´ end of the primer could be invoked to explain the observed differences, although further studies will be necessary to provide a reliable mechanistic interpretation.
In agreement with the results obtained with purified RTs, phenotypic assays revealed that the recombinant HIV-1 containing mutations M41L/A62V/T69SSS/K70R/V75I/T215Y was about 18 times more susceptible to AZT than its homologous lacking the V75I change. These results were also consistent with the predicted AZT fold-change values of 3. had a relatively small impact on d4T resistance in phenotypic assays, as a consequence of the inhibition of the excision reaction by the relatively high dNTP levels found in the MT-4 cells used in the drug susceptibility assays. Phenotypic assays with recombinant HIV-1 clones also showed that the addition of V75I to an RT sequence background containing M41L, A62V, T69S, K70R, V75I, T215Y, and the Ser-Ser insertion between positions 69 and 70 had an antagonistic effect on d4T resistance.
Our results demonstrate that V75I shares a common biochemical mechanism with RT mutations such as K65R (21, 54) , L74V (19, 20) , Y181C (55), M184V (17, 18) , as well as with a number of foscarnet-related resistance mutations (i.e. W88G, E89K, A114S, S117T, Q161L and M164I) (56, 57) and with the deletion of Thr69, which is often associated with the Q151M complex (58-60). All of those mutations increase HIV-1 susceptibility to AZT by reducing the phosphorolytic activity of the enzyme. Phenotypic drug susceptibility assays have demonstrated that as in the case of V75I, other amino acid changes (e.g. K65R, L74V, W88G, E89K, L92I, A114S, S117T, S156A, F160Y, Q161L, M164I, Y181C, M184V) are able to enhance AZT susceptibility in the presence of TAMs (17, 20, 21, (55) (56) (57) 61, 62) . V75I impairs excision by reducing the rate of chain-terminator removal. Moreover, in the presence of TAMs, V75I contributes to increase the IC 50 for the next complementary nucleotide, by facilitating the pretranslocation configuration of the d4TMP-terminated primer. However, the effects of V75I on the formation of a dead-end complex with primers terminated with d4T could be of little significance due to the relatively small differences between the IC 50 values obtained with excision-proficient RTs with or without V75I. On the other hand, as in the case of L74V or M184V (19), V75I does not affect the translocational equilibrium in the presence of the next complementary dNTP when the primer is blocked with AZTMP.
The relevance of the ATP-dependent phosphorolytic mechanism in vivo depends on the concentration of ATP, and the dNTP levels inside the cell. Estimates of dNTP concentrations ranged from 0.2 μM to 24.5 μM in resting human lymphocytes, while concentrations can be 2-to 10-fold higher in activated human lymphocytes, depending on the assay conditions and dNTP analysed. The highest dNTP levels have been reported for established cell lines, such as H-9, U937 promonocytes, CEM lymphoblasts or SupT1 cells, where nucleotide concentrations range from 50 μM to 300 μM (for reviews, see refs. 63, 64) . Under these conditions, it is clear that rescue of inhibitor-terminated primers could be more relevant for the acquisition of resistance to AZT than for d4T (41, 48) .
Despite the extensively reported evidence of cross-resistance between AZT and d4T in clinical settings (65) (66) (67) , the relatively high dNTP levels could explain the large differences between AZT and d4T susceptibilities obtained in phenotypic assays (65, 68, 69) .
For example, M41L/L210W/T215Y confers >100-fold increased resistance to AZT in phenotypic assays, but only a 2.1-fold increase in the IC 50 for d4T relative to the wild-type HIV-1 (70) . In contrast, in the presence of M184V, M41L/L210W/T215Y conferred 15-fold increased resistance to AZT, but a mere 1.8-fold increased resistance to d4T. It is widely accepted that M184V impairs excision of thymidine analogues (17, 18) , but in phenotypic assays these effects which are clearly detectable with AZT, are only marginal with d4T, due to the high dNTP levels present in SupT1 and MT-4 cells. In this context, our phenotypic data showing a 2-fold reduction of the IC 50 for d4T when V75I is present are most significant. The biochemical studies reported in this work also suggest that this reduction is a consequence of the lower d4TMP excision rate of the V75I-containing RT, rather than an effect of its decreased susceptibility to dNTP inhibition.
An extensive analysis of amino acid covariation in RT sequences from more than 7,000 people infected with HIV-1 group M:subtype B virus obtained from the Stanford HIV Drug Resistance Database has revealed that V75I is strongly associated with mutations of the Q151M complex, whereas V75M is positively associated with TAMs such as M41L, L210W or T215Y (71) . The antagonistic effects between V75I and TAMs could be relevant for the acquisition of AZT resistance in HIV-2. Wild-type HIV-2 RT contains Ser instead of Thr at position 215 and only one nucleotide change is needed to obtain the substitution S215Y. However, Q151M emerges as the major AZT resistance mutation in HIV-2 RT, whereas TAMs are relatively uncommon in HIV-2-infected patients (72) (73) (74) . Molecular modelling studies suggested that several amino acid differences around the putative ATP binding site of HIV-2 RT in comparison with the HIV-1 RT could account for these differences (75) . The presence of Ile75 in the wild-type HIV-2 RT and our results showing the diminished excision activity conferred by V75I provide additional arguments to explain why the Q151M pathway is preferred over the accumulation of TAMs in the acquisition of thymidine analogue resistance in HIV-2.
Finally, it should be noted that our study also reveals that accessory mutations in the Q151M complex could have different effects on excision, since we have previously demonstrated that A62V contributes to increase ATP-mediated excision of thymidine analogues in the presence of one, two or three TAMs (16) . From a mechanistic point of view, antagonistic mutations are likely to affect the optimal alignment of the PPi donor with the phosphodiester group located at the 3´ end of the blocked primer. A more complete understanding of the precise mechanisms underlying these interactions may come from the determination of the crystal structures of ternary complexes containing RTs carrying the relevant combinations of mutations.
